000			04574nam a2200433 c 4500
999			_c330973 _d330973 _x1
001			330973
003			ES-MaUEC
005			20230102114634.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			210216s2021 gw | s |||| 0|eng d
020			_a9783030568245
024	7		_a10.1007/978-3-030-56824-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _erda _dES-MaUEC
050		4	_aRC927 _b2021 EB
245	0	0	_aRheumatic Diseases and Syndromes Induced by Cancer Immunotherapy : _bA Handbook for Diagnosis and Management _cedited by Maria E. Suarez-Almazor, Leonard H. Calabrese
250			_aFirst edition 2021
264		1	_aCham, Switzerland _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XIV, 363 páginas) _b19 ilustraciones, 16 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
505	0		_aPART 1 - INTRODUCTION -- 1. Cancer Immunology and the evolution of immunotherapy -- 2. Cancer immunotherapy: overview -- 3. Pathogenesis of immune-related adverse events -- PART 2 - IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS -- 4. Arthritis -- 5. Polymyalgia rheumatica -- 6. Myositis -- 7. Sicca syndromes -- 8. Sarcoidosis -- 9. Miscellaneous rheumatic syndromes -- 10. Non-rheumatic immune-related adverse events -- 11. Immune-related adverse events with other cancer immunotherapies -- PART 3 - CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES -- 12. Inflammatory arthritis -- 13. Other rheumatic autoimmune diseases -- 14. Choosing the right therapy -- 15. Risk-benefit considerations -- 16. Patient education and shared-decision making.
520	3		_aWith the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk-benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.
988			_aSpringer_Medicine_2021
650		7	_2embne _aReumatismo _9138755
650		7	_2embne _9142010 _aEnfermedades inmunológicas
650		7	_2embne _aInmunoterapia _9145440
700	1		_aSuárez-Almazor, María E. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aCalabrese, Leonard H _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030568238
776	0	8	_iPrinted edition: _z9783030568252
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-56824-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b04/2021 _dz _ea _zSI